NuCana plc (NASDAQ:NCNA) Short Interest Down 49.1% in March

NuCana plc (NASDAQ:NCNA) was the recipient of a large decline in short interest in March. As of March 15th, there was short interest totalling 8,800 shares, a decline of 49.1% from the February 28th total of 17,300 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average daily volume of 113,200 shares, the short-interest ratio is presently 0.1 days.

Institutional Investors Weigh In On NuCana

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Two Sigma Securities LLC bought a new stake in shares of NuCana during the 4th quarter valued at $25,000. Citadel Advisors LLC bought a new stake in NuCana during the fourth quarter worth about $30,000. Virtu Financial LLC purchased a new stake in NuCana in the fourth quarter worth about $48,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of NuCana during the fourth quarter valued at approximately $54,000. 44.00% of the stock is owned by hedge funds and other institutional investors.

NuCana Stock Performance

Shares of NASDAQ NCNA traded up $0.21 during midday trading on Friday, hitting $1.28. 546,725 shares of the company traded hands, compared to its average volume of 427,030. NuCana has a 12-month low of $0.69 and a 12-month high of $10.79. The firm has a market cap of $3.38 million, a P/E ratio of -0.12 and a beta of 0.89. The stock has a 50-day moving average price of $0.96 and a 200 day moving average price of $1.47.

NuCana (NASDAQ:NCNA) last posted its earnings results on Thursday, March 20th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.43) by $2.11. As a group, equities analysts expect that NuCana will post -13.42 earnings per share for the current year.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.